

# ATLAS

**Country:** United Kingdom

**Group:** Adjuvant Tamoxifen – Longer Against Shorter (**ATLAS**)

---

**Chair:** C. Williams  
MRC/BHF Clinical Trial Service and Epidemiological Studies Unit  
The Richard Doll Building  
Roosevelt Drive  
OXFORD, OX3 7LF  
UNITED KINGDOM  
Tel: +44 1865 743844  
Fax: +44 1865 743982

**Principal Investigator:** C. Davies  
The ATLAS Trial Office  
MRC/BHF Clinical Trial Service and Epidemiology Studies Unit  
The Richard Doll Building  
Roosevelt Drive  
OXFORD, OX3 7LF  
UNITED KINGDOM  
Tel: +44 1865 743840  
Fax: +44 1865 743982  
Email: christina.davies@ctsu.ox.ac.uk

**ATLAS Trial Office:** MRC/BHF Clinical Trial Service and Epidemiology Studies Unit  
The Richard Doll Building  
Roosevelt Drive  
OXFORD, OX3 7LF  
UNITED KINGDOM  
Tel: +44 1865 743844  
Fax: +44 1865 743982  
Email: atlas@ctsu.ox.ac.uk

**Website:** [www.ctsu.ox.ac.uk](http://www.ctsu.ox.ac.uk)

**Title:** Phase III ATLAS adjuvant tamoxifen – longer against shorter: an international trial of adjuvant hormonal treatment duration ([www.ctsu.ox.ac.uk/~atlas/index.html](http://www.ctsu.ox.ac.uk/~atlas/index.html)).

**Coordinator(s):** Dr C. Davies  
 ATLAS Trial Office  
 MRC/BHF Clinical Trial Service and Epidemiological Studies Unit  
 The Richard Doll Building  
 Roosevelt Drive  
 OXFORD, OX3 7LF  
 UNITED KINGDOM  
 Tel: +44 1865 743840  
 Fax: +44 1865 743982  
 Email: [christina.davies@ctsu.ox.ac.uk](mailto:christina.davies@ctsu.ox.ac.uk)


**Summary:**

- Opened in June 1996
- Completed accrual in March 2005 with ~15,250 randomized
- Follow-up to continue until at least 2010 to gather information on recurrence, second primary cancers, hospitalization and cause of death

*Objective:*

- To assess reliably the balance of risks of prolonging adjuvant tamoxifen by at least 5 years among women who have already had about 5 years of tamoxifen and for whom there is uncertainty about whether they should stop now, or continue for a few years longer. There were no restrictions in this trial on hormonal status, age or nodal status at the time of diagnosis with the primary eligibility criterion being substantial uncertainty about whether to stop or continue tamoxifen (see above).

**Scheme:**



**Update:**

- 15,252 patients entered to date (March 2005): recruitment closed. Primary endpoint – all-cause mortality supplemented by analyses of recurrence-free survival, second primary cancers and non-fatal events leading to hospitalization. For further information, see ATLAS website ([www.ctsu.ox.ac.uk/~atlas/index.html](http://www.ctsu.ox.ac.uk/~atlas/index.html)).

- Related Publications:** Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials (*The Lancet* 2005; 365: 1687–1717).  
<http://www.ctsu.ox.ac.uk/~ebctcg/>
- Topics:**
- Tamoxifen duration
  - Tamoxifen
  - Hormonal therapy
- Keywords:** Large-scale randomized trial, adjuvant tamoxifen, hormonal treatment duration, survival